First Light Asset Management, LLC Krystal Biotech, Inc. Transaction History

First Light Asset Management, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $7.43 Million - $12.3 Million	-94,721 Reduced 48.33%	101,259 $11.9 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $20.1 Million - $23.4 Million	-277,711 Reduced 58.63%	195,980 $15.7 Million
Q4 2022 Feb 14, 2023	SELL	$63.14 - $79.9 $1.19 Million - $1.51 Million	-18,864 Reduced 3.83%	473,691 $37.5 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $6.68 Million - $8.49 Million	-103,057 Reduced 17.3%	492,555 $34.3 Million
Q2 2022 Aug 12, 2022	SELL	$48.93 - $73.47 $5.99 Million - $8.99 Million	-122,324 Reduced 17.04%	595,612 $39.1 Million
Q1 2022 May 13, 2022	BUY	$51.99 - $72.11 $1.96 Million - $2.72 Million	37,766 Added 5.55%	717,936 $47.8 Million
Q4 2021 Feb 14, 2022	BUY	$39.81 - $88.24 $1.86 Million - $4.12 Million	46,689 Added 7.37%	680,170 $47.6 Million
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $5.56 Million - $7.67 Million	106,831 Added 20.29%	633,481 $33.1 Million
Q2 2021 Aug 13, 2021	BUY	$62.14 - $81.82 $2.18 Million - $2.88 Million	35,139 Added 7.15%	526,650 $35.8 Million
Q1 2021 May 17, 2021	SELL	$59.42 - $85.46 $13,607 - $19,570	-229 Reduced 0.05%	491,511 $37.9 Million
Q4 2020 Feb 16, 2021	BUY	$40.64 - $61.38 $1.1 Million - $1.66 Million	27,077 Added 5.83%	491,740 $29.5 Million
Q3 2020 Nov 13, 2020	BUY	$37.76 - $48.49 $18,275 - $23,469	484 Added 0.1%	464,663 $20 Million
Q2 2020 Aug 14, 2020	BUY	$37.03 - $60.0 $17.2 Million - $27.9 Million	464,179 New	464,179 $19.2 Million

309

24.3M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.06B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of First Light Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on First Light Asset Management, LLC with notifications on news.